Metis TechBio company profile
Company profile
Metis TechBio has 150 employees and is headquartered in Beijing, China.
Metis TechBio develops AI-driven nanomaterial tools for delivering active agents across carbon-based life forms, with research work in Chinese Mainland and the United States. Its NanoForge suite pairs a lipid compound collection with machine-learning models, molecular simulation and automated screening systems. Further platforms named AiTEM, AiLNP and AiRNA model how nanoscale particles interact, supporting the design, optimization and validation of nanomaterials and their payloads. Customers include pharmaceutical companies, biotechnology firms and medical research institutions, and the company was formerly named Hangzhou Jitai Pharmaceutical Technology.
In the fiscal year ended December 2025, revenue was 105 million yuan and the net loss reached 391.8 million yuan. The company employs 150 people and is headquartered in Beijing, where it was incorporated in 2020. It has a strategic partnership with Eli Lilly and Company.
Company facts
- Sector
- Materials
- Industry
- Biotechnology
- Country
- Hong Kong SAR China
- Headquarters
- Room 201, 2/F, Building 13, Beijing
- Employees
- 150
- Chief executive
- Tsai-Ta Lai
- Founded
- 2020
- Fiscal year
- January - December
- Listing
- 7666 · HKEX
- Currency
- HKD
- ISIN
- CNE100007LD1
- Website
- metistechbio.com
Metis TechBio and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Metis TechBio7666 | Hong Kong SAR China | $1.11B | 150 | -131.2% | — |
| MesoblastMSB | Australia | $1.48B | 108 | -42.6% | — |
| Neuren PharmaceuticalsNEU | Australia | $1.83B | 8 | 19.9% | 144.0 |
| InSilico Medicine Cayman TopCo3696 | Hong Kong SAR China | $2.59B | 333 | -6.9% | — |
| Telix PharmaceuticalsTLX | Australia | $2.92B | 1,120 | 6.2% | 92.3 |
| 3SBio1530 | Hong Kong SAR China | $4.56B | 6,068 | 60.3% | 3.90 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
